Candel Therap 
Welcome,         Profile    Billing    Logout  
 2 Products   2 Diseases  2 Products   10 Trials   214 News 
16 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
ProstAtak (aglatimagene besadenovec) / Candel Therap
ChiCTR-TRC-09000387: Clinical Program of Licartin Combined with ADV-TK for Prevention of Hepatocellular Carcinoma Recurrence after Liver Transplantation

Completed
4
200
 
Conventional therapy after liver transplantation+ first therapy of intravenous injection with Licartin at the first weekend, the third weekend, sixth weekend of post-liver transplantation, totally 3 cycles. ;Control group: conventional therapy after liver transplantation and receive placebo at the time of therapy. ;Injection of ADV-TK into peritoneum tissues around the liver during the liver transplantation operation and at week 3 and week 5 of post-operation.Intravenous injections of Licartin after each cycle of ADV-TK were administerted at the end of week 1, 3 and 6 for 3 times. ;Injection of ADV-TK into peritoneum tissues around the liver during the liver transplantation operation. The second and third injections of ADV-TK were administerted at week 3 and week 5 of post-operation. Ganciclovir was injected i.v. 36 h after administration of ADV-TK for 14 days.
Fourth Military Medical University; Ministry of Science and Technology, P.R. China, The Ministry of Sciences and Technology of People's Republic of China
Hepatocellular carcinoma
 
 
PrTK03, NCT01436968: Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer

Active, not recruiting
3
711
US
Aglatimagene besadenovec + valacyclovir, AdV-tk, CAN-2409, Placebo + valacyclovir
Candel Therapeutics, Inc.
Prostate Cancer
12/24
12/24
ChiCTR-ONRC-11001232: Phase II study of Recombinant Adenovirus-Herpes Simplex Virus Thymidine Kinase (ADV-TK) combined with Ganciclovir in recurrent head and neck cancer of late-stage

Completed
2
41
 
Recombinant Adenovirus-Herpes Simplex Virus Thymidine Kinase (ADV-TK) combined with Ganciclovir
Shenzhen Tiandakang Gene Engineering Co., Ltd.,; Wuhan Tiandakang Biotech Engineering Co., Ltd., Shenzhen Tiandakang Gene Engineering Co., Ltd.
Head and neck cancer in late-stage
 
 
ChiCTR-ONRC-11001233: Phase II study of Recombinant Adenovirus-Herpes Simplex Virus Thymidine Kinase (ADV-TK) combined with Ganciclovir in primary hepatocellular carcinoma

Completed
2
43
 
Recombinant Adenovirus-Herpes Simplex Virus Thymidine Kinase (ADV-TK) combined with Ganciclovir
Shenzhen Tiandakang Gene Engineering Co., Ltd.; Wuhan Tiandakang Bio-Tech Engineering Co., Ltd., Shenzhen Tiandakang Gene Engineering Co., Ltd.
Primary hepatocellular carcinoma in late stage
 
 
STOMP, NCT03004183: SBRT and Oncolytic Virus Therapy Before Pembrolizumab for Metastatic TNBC and NSCLC

Completed
2
57
US
ADV/HSV-tk, Valacyclovir, valacyclovir hydrochloride, SBRT, Pembrolizumab, Keytruda
The Methodist Hospital Research Institute, Merck Sharp & Dohme LLC
Metastatic Non-small Cell Lung Cancer, Metastatic Triple-negative Breast Cancer
07/22
01/24
NCT03541928: Phase II High Risk Prostate Cancer Trial Using Gene & Androgen Deprivation Therapies, Radiotherapy, & Surgery

Recruiting
2
60
US
HSV-Tk, Gene therapy, AdV-tk gene therapy, Herpes simplex virus thymidine kinase, Valacyclovir, Valtrex, Bicalutamide, Casodex, Leuprolide Acetate, Lupron, Brachytherapy, External beam radiotherapy, HDR, EBRT, Radical prostatectomy, Prostatectomy
The Methodist Hospital Research Institute
High-risk Prostate Cancer, Prostate Cancer
07/23
07/23
ULYSSES, NCT02768363: Randomized Controlled Trial of CAN-2409 Immunotherapy During Active Surveillance for Prostate Cancer

Active, not recruiting
2
187
US, RoW
aglatimagene besadenovec, AdV-tk, CAN-2409, placebo, valacyclovir
Candel Therapeutics, Inc.
Prostate Cancer
12/24
 
LuTK02, NCT04495153: CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC

Active, not recruiting
2
90
US
Aglatimagene besadenovec, CAN-2409, AdV-tk
Candel Therapeutics, Inc., NYU Langone Health
Non Small Cell Lung Cancer
12/24
12/26
PaTK02, NCT02446093: Neoadjuvant CAN-2409 in Combination With Chemoradiation or SBRT for Borderline Resectable Pancreatic Adenocarcinoma

Active, not recruiting
2
54
US, RoW
Aglatimagene besadenovec, CAN-2409, AdV-tk, Chemoradiation, Stereotactic body radiation therapy, Surgery
Candel Therapeutics, Inc., Mayo Clinic
Borderline Resectable Pancreatic Adenocarcinoma
12/25
07/26
NCT03596086: HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM

Recruiting
1/2
62
US
ADV/HSV-tk (gene therapy), gene transfer, gene therapy, HSV-tk
David Baskin MD, Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital Research Institute
Glioblastoma Multiforme, Astrocytoma, Grade III
12/25
12/25
NCT03603405: HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM

Recruiting
1/2
62
US
ADV/HSV-tk (gene therapy), gene therapy, gene therapy, HSV-tk
The Methodist Hospital Research Institute
Glioblastoma, Anaplastic Astrocytoma
12/25
12/25
NCT03131037: Intratumoral Gene Mediated Cytotoxic Immunotherapy in Patients With Resectable Non-Small Cell Lung Cancer

Active, not recruiting
1
12
US
CAN-2409 + valacyclovir
Candel Therapeutics, Inc., University of Pennsylvania
Lung Cancer
12/21
12/24
GMCI, NCT03576612: , Nivolumab, and Radiation Therapy in Treating Patients with Newly Diagnosed High-Grade Gliomas

Completed
1
41
US
AdV-tk, Aglatimagene Besadenovec, Valacyclovir, 124832-26-4, L-Valine ester with 9-((2-hydroxyethoxy)methyl)guanine, Zelitrex, Radiation, Irradiate, irradiation, radiotherapy, RT, Temozolomide, TMZ, Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo, Laboratory Biomarker Analysis
Candel Therapeutics, Inc., National Cancer Institute (NCI), Bristol-Myers Squibb
Glioma, Malignant
06/23
06/23
ChiCTR-ONRC-12002985: New clinical stategy for hepatocellular carcinoma therapy combined with adjuvant adenovirus-thymidine kinase gene

Completed
N/A
360
 
Liver transplantation combined with ADV-TK gene ;The hepatic resection combined with ADV-TK gene ;TACE+radio frequency combined with ADV-TK gene
Beijing YouAn Hospital, Capital Medical University; None, The national
Primary hepatocellular carcinoma
 
 
ChiCTR1900025561: Assessing the Safety and Efficacy of an Imaging Probe 18F-FHBG for ADV-TK Gene Therapy Trials in Recurrent Glioblatoma Multiform

Not yet recruiting
N/A
20
 
whole body PET/CT scanning with 18F-FHBG
Beijing Tiantan Hospital, Capital Medical University; Beijing Tiantan Hospital, Capital Medical University, Beijing Science and Technology Star Talent Project (xx2017017), 350,000 RMB yuan
Brain recurrent glioblastoma multiform
 
 
CAN-3110 / Candel Therap
rQNestin, NCT03152318: A Study of the Treatment of Recurrent Malignant Glioma With 34.5v.2

Recruiting
1
62
US
rQNestin, rQNestin34.5v.2, CAN-3110, Cyclophosphamide, Cytoxan®, Neosar®, Stereotactic biopsy
Dana-Farber Cancer Institute, National Institutes of Health (NIH), Candel Therapeutics, Inc.
Malignant Glioma of Brain, Astrocytoma, Malignant Astrocytoma, Oligodendroglioma, Anaplastic Oligodendroglioma of Brain (Diagnosis), Mixed Oligo-Astrocytoma, Ependymoma, Ganglioglioma, Pylocytic/Pylomyxoid Astrocytoma, Brain Tumor, Glioma, Brain Cancer, Glioblastoma, Glioblastoma Multiforme
06/25
06/26
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
ProstAtak (aglatimagene besadenovec) / Candel Therap
ChiCTR-TRC-09000387: Clinical Program of Licartin Combined with ADV-TK for Prevention of Hepatocellular Carcinoma Recurrence after Liver Transplantation

Completed
4
200
 
Conventional therapy after liver transplantation+ first therapy of intravenous injection with Licartin at the first weekend, the third weekend, sixth weekend of post-liver transplantation, totally 3 cycles. ;Control group: conventional therapy after liver transplantation and receive placebo at the time of therapy. ;Injection of ADV-TK into peritoneum tissues around the liver during the liver transplantation operation and at week 3 and week 5 of post-operation.Intravenous injections of Licartin after each cycle of ADV-TK were administerted at the end of week 1, 3 and 6 for 3 times. ;Injection of ADV-TK into peritoneum tissues around the liver during the liver transplantation operation. The second and third injections of ADV-TK were administerted at week 3 and week 5 of post-operation. Ganciclovir was injected i.v. 36 h after administration of ADV-TK for 14 days.
Fourth Military Medical University; Ministry of Science and Technology, P.R. China, The Ministry of Sciences and Technology of People's Republic of China
Hepatocellular carcinoma
 
 
PrTK03, NCT01436968: Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer

Active, not recruiting
3
711
US
Aglatimagene besadenovec + valacyclovir, AdV-tk, CAN-2409, Placebo + valacyclovir
Candel Therapeutics, Inc.
Prostate Cancer
12/24
12/24
ChiCTR-ONRC-11001232: Phase II study of Recombinant Adenovirus-Herpes Simplex Virus Thymidine Kinase (ADV-TK) combined with Ganciclovir in recurrent head and neck cancer of late-stage

Completed
2
41
 
Recombinant Adenovirus-Herpes Simplex Virus Thymidine Kinase (ADV-TK) combined with Ganciclovir
Shenzhen Tiandakang Gene Engineering Co., Ltd.,; Wuhan Tiandakang Biotech Engineering Co., Ltd., Shenzhen Tiandakang Gene Engineering Co., Ltd.
Head and neck cancer in late-stage
 
 
ChiCTR-ONRC-11001233: Phase II study of Recombinant Adenovirus-Herpes Simplex Virus Thymidine Kinase (ADV-TK) combined with Ganciclovir in primary hepatocellular carcinoma

Completed
2
43
 
Recombinant Adenovirus-Herpes Simplex Virus Thymidine Kinase (ADV-TK) combined with Ganciclovir
Shenzhen Tiandakang Gene Engineering Co., Ltd.; Wuhan Tiandakang Bio-Tech Engineering Co., Ltd., Shenzhen Tiandakang Gene Engineering Co., Ltd.
Primary hepatocellular carcinoma in late stage
 
 
STOMP, NCT03004183: SBRT and Oncolytic Virus Therapy Before Pembrolizumab for Metastatic TNBC and NSCLC

Completed
2
57
US
ADV/HSV-tk, Valacyclovir, valacyclovir hydrochloride, SBRT, Pembrolizumab, Keytruda
The Methodist Hospital Research Institute, Merck Sharp & Dohme LLC
Metastatic Non-small Cell Lung Cancer, Metastatic Triple-negative Breast Cancer
07/22
01/24
NCT03541928: Phase II High Risk Prostate Cancer Trial Using Gene & Androgen Deprivation Therapies, Radiotherapy, & Surgery

Recruiting
2
60
US
HSV-Tk, Gene therapy, AdV-tk gene therapy, Herpes simplex virus thymidine kinase, Valacyclovir, Valtrex, Bicalutamide, Casodex, Leuprolide Acetate, Lupron, Brachytherapy, External beam radiotherapy, HDR, EBRT, Radical prostatectomy, Prostatectomy
The Methodist Hospital Research Institute
High-risk Prostate Cancer, Prostate Cancer
07/23
07/23
ULYSSES, NCT02768363: Randomized Controlled Trial of CAN-2409 Immunotherapy During Active Surveillance for Prostate Cancer

Active, not recruiting
2
187
US, RoW
aglatimagene besadenovec, AdV-tk, CAN-2409, placebo, valacyclovir
Candel Therapeutics, Inc.
Prostate Cancer
12/24
 
LuTK02, NCT04495153: CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC

Active, not recruiting
2
90
US
Aglatimagene besadenovec, CAN-2409, AdV-tk
Candel Therapeutics, Inc., NYU Langone Health
Non Small Cell Lung Cancer
12/24
12/26
PaTK02, NCT02446093: Neoadjuvant CAN-2409 in Combination With Chemoradiation or SBRT for Borderline Resectable Pancreatic Adenocarcinoma

Active, not recruiting
2
54
US, RoW
Aglatimagene besadenovec, CAN-2409, AdV-tk, Chemoradiation, Stereotactic body radiation therapy, Surgery
Candel Therapeutics, Inc., Mayo Clinic
Borderline Resectable Pancreatic Adenocarcinoma
12/25
07/26
NCT03596086: HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM

Recruiting
1/2
62
US
ADV/HSV-tk (gene therapy), gene transfer, gene therapy, HSV-tk
David Baskin MD, Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital Research Institute
Glioblastoma Multiforme, Astrocytoma, Grade III
12/25
12/25
NCT03603405: HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM

Recruiting
1/2
62
US
ADV/HSV-tk (gene therapy), gene therapy, gene therapy, HSV-tk
The Methodist Hospital Research Institute
Glioblastoma, Anaplastic Astrocytoma
12/25
12/25
NCT03131037: Intratumoral Gene Mediated Cytotoxic Immunotherapy in Patients With Resectable Non-Small Cell Lung Cancer

Active, not recruiting
1
12
US
CAN-2409 + valacyclovir
Candel Therapeutics, Inc., University of Pennsylvania
Lung Cancer
12/21
12/24
GMCI, NCT03576612: , Nivolumab, and Radiation Therapy in Treating Patients with Newly Diagnosed High-Grade Gliomas

Completed
1
41
US
AdV-tk, Aglatimagene Besadenovec, Valacyclovir, 124832-26-4, L-Valine ester with 9-((2-hydroxyethoxy)methyl)guanine, Zelitrex, Radiation, Irradiate, irradiation, radiotherapy, RT, Temozolomide, TMZ, Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo, Laboratory Biomarker Analysis
Candel Therapeutics, Inc., National Cancer Institute (NCI), Bristol-Myers Squibb
Glioma, Malignant
06/23
06/23
ChiCTR-ONRC-12002985: New clinical stategy for hepatocellular carcinoma therapy combined with adjuvant adenovirus-thymidine kinase gene

Completed
N/A
360
 
Liver transplantation combined with ADV-TK gene ;The hepatic resection combined with ADV-TK gene ;TACE+radio frequency combined with ADV-TK gene
Beijing YouAn Hospital, Capital Medical University; None, The national
Primary hepatocellular carcinoma
 
 
ChiCTR1900025561: Assessing the Safety and Efficacy of an Imaging Probe 18F-FHBG for ADV-TK Gene Therapy Trials in Recurrent Glioblatoma Multiform

Not yet recruiting
N/A
20
 
whole body PET/CT scanning with 18F-FHBG
Beijing Tiantan Hospital, Capital Medical University; Beijing Tiantan Hospital, Capital Medical University, Beijing Science and Technology Star Talent Project (xx2017017), 350,000 RMB yuan
Brain recurrent glioblastoma multiform
 
 
CAN-3110 / Candel Therap
rQNestin, NCT03152318: A Study of the Treatment of Recurrent Malignant Glioma With 34.5v.2

Recruiting
1
62
US
rQNestin, rQNestin34.5v.2, CAN-3110, Cyclophosphamide, Cytoxan®, Neosar®, Stereotactic biopsy
Dana-Farber Cancer Institute, National Institutes of Health (NIH), Candel Therapeutics, Inc.
Malignant Glioma of Brain, Astrocytoma, Malignant Astrocytoma, Oligodendroglioma, Anaplastic Oligodendroglioma of Brain (Diagnosis), Mixed Oligo-Astrocytoma, Ependymoma, Ganglioglioma, Pylocytic/Pylomyxoid Astrocytoma, Brain Tumor, Glioma, Brain Cancer, Glioblastoma, Glioblastoma Multiforme
06/25
06/26

Download Options